Tianda Pharmaceuticals Limited

Equities

455

KYG887471038

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:16 2024-04-24 am EDT 5-day change 1st Jan Change
0.265 HKD 0.00% Intraday chart for Tianda Pharmaceuticals Limited +7.72% +21.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Current Year from 1 January 2023 to 31 December 2023 CI
Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023 CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tianda Pharmaceuticals to Shrink H1 Loss by Over 70% MT
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023 CI
Tianda Unit Buys Out 45% Stake in Meng Sheng Pharmaceutical MT
Tianda Pharmaceuticals Limited entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million. CI
Tianda Pharmaceuticals Limited Announces Board Changes CI
Tianda Pharmaceuticals Limited Approves Final Dividend CI
Tianda Pharmaceuticals Limited Proposes Final Dividend for the Nine Months Ended 31 December 2022, Payable on or Before, 14 July 2023 CI
Tianda Pharmaceuticals Unit to Invest HK$10 Million in Fund MT
Beijing Tong Ren Tang Chinese Medicine’s CEO Redesignated; New CEO Named MT
Tianda Pharmaceuticals Limited Announces Final Ordinary Dividend for the Nine Months Ended 31 December 2023 CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022 CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022 CI
Tianda Pharmaceuticals Warns of Higher Loss in Fiscal Nine-Month Period; Shares Tumble 9% MT
Tianda Pharmaceuticals Limited Provides Group Earnings Guidance for the Nine Months Period from April 1, 2022 to December 31, 2022 CI
Tianda Pharmaceuticals to Set Up Additional Production Line to Meet Rising Medicine Demand MT
Tianda Pharmaceuticals' Loss for Half Year Through September Narrows MT
Tianda Pharmaceuticals Limited Announces Changes in Financial Year End Date CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Tianda Pharmaceuticals Chairman Buys 1.9 Million Shares; Stock Rises 3% MT
Tianda Pharmaceuticals Limited Declares Final Dividend CI
Chart Tianda Pharmaceuticals Limited
More charts
Tianda Pharmaceuticals Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The Company operates businesses in Hong Kong, China and Australia.
More about the company
  1. Stock Market
  2. Equities
  3. 455 Stock
  4. News Tianda Pharmaceuticals Limited
  5. Tianda Pharmaceuticals Concludes Nearly $22 Million Sale of Former R&D Facility